Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
LONDON, BOSTON, TOKYO (June 6, 2018) — Orphan drugs are forecast to remain one of the fastest growth areas of the global pharmaceutical market according to Evaluate’s annual industry report, the “EvaluatePharma World Preview 2018, Outlook to 2024”. The rare disease space is predicted to capture 20% of the total $1.2trn market in 2024. Supporting this growth are the launches of novel therapies, including gene and cell therapies, as well as increased access to medicines globally.
Evaluate’s report also highlights factors that could act as a brake on industry growth, including the threat of biosimilars or genericisation for some of the industry’s biggest products. The report shows $251bn of sales at risk between 2018 and 2024, teeing up a second patent cliff for the industry.
Additional findings from the report include:
Life science commercial intelligence firm Evaluate publishes their complimentary industry report, the “EvaluatePharma World Preview 2018, Outlook to 2024” at the annual BIO International Convention in Boston, June 4-7, 2017, Booth #2455. The report sets the industry standard for consensus forecasts for pharmaceutical and biotech companies, bringing together key analyses from the world’s financial markets to provide insight into the expected performance between now and 2024.
Download the full report at www.evaluate.com/PharmaWorldPreview2018.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries.
Our EvaluatePharma® online subscription services provides a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provide thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a trusted partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.